潜在“first-in-class”抗癌小分子获FDA优先审评资格】2月18日,Chimerix公司宣布,美国FDA已受理该公司为在研疗法dordaviprone递交的新药申请(NDA),用于治疗复发性H3 K27M突变弥漫性胶质瘤患者。FDA同时授予该申请优先审评资格,预计在2025年8月18日之前完成审评。Dordaviprone是一款潜在“first-in-class”小分子...
【First-in-class药设系列】靶向ClpP的激动剂设计及其在肺鳞状细胞癌中研究 肺鳞癌(Lung squamous cell carcinoma, LUSC)约占非小细胞肺癌的30%。目前,LUSC的主要治疗手段有化疗,放疗,免疫治疗以及靶向治疗,而目前靶向治疗LUSC治疗效果差,具有严重的不良事件,而免疫治疗的应答率相对较低,急需发现新靶标及治疗新策略。
Dordaviprone获FDA优先审评资格】北京时间2025年2月19日,Chimerix公司日宣布,美国FDA已受理该公司为在研疗法dordaviprone递交的新药申请(NDA),用于治疗复发性H3 K27M突变弥漫性胶质瘤患者。FDA同时授予该申请优先审评资格,预计在2025年8月18日之前完成审评。 Dordaviprone(ONC201)是一款潜在“first-in-class”小...
On top of their already diverse functions in the physiological context, an additional role was discovered over the last years for this class of protein, namely to serve as a target for antibiotic action. Especially the conserved proteolytic core component of the protease machinery, designated ClpP,...
人B类清道夫受体1(SCARB1)elisa试剂盒 Scenger Receptor Class B Member 1/SCARB1 kit 人8--2-脱氧鸟苷(8-OH-dG)elisa试剂盒 8-hydroxy-2-deoxyguanosine/8-OH-dG kit 人尾肢同源蛋白2(PYGO2;PP7910)elisa试剂盒 PYGO2;PP7910/PYGO2;PP7910 kit 人双肾上腺皮质(DCX)elisa试剂盒 Doublecortin/DCX ki...
ONC201 and ONC212 are a class of anti-cancer compounds that effectively kill cancer cells, but are much less toxic to normal cells (Allen et al., 2013, Ishizawa et al., 2016). Their efficacy is independent of TP53 mutation status (Allen et al., 2013, Ishizawa et al., 2016). ...
Class Monoclonal Type Antibody Full Name ClpP caseinolytic peptidase, ATP-dependent, proteolytic subunit homolog (E. coli) Synonyms CLPP, Endopeptidase Clp Calculated Molecular Weight 30 kDa Observed Molecular Weight 26 kDa, 30 kDa GenBank Accession Number BC002956 Gene Symbol CLPP Gene ID (NCBI) ...
Different with conventional antibiotics those are typical inhibitors, small﹎olecule activators of bacterial ClpP represent a new class of antibiotics. No ClpP activators have been developed for clinical trial. Herein, we conducted a screening on our library of bengamide﹍ike ring﹐pened analogues and...
In contrast, ADEPs are a class of natural product-derived cyclic acyldepsipeptides that act as potent antibiotics through the dysregulation and activation of ClpP9,10. In an unperturbed cell, proteolysis occurs through binding of a AAA þ chaperone such as ClpX to the apical sides of the ...
The imipridone family is another family of anticancer compounds recently identified as ClpP activators82. ONC201 is the first-in-class imipridones that is in clinical trials for multiple advanced cancer. Although initially was thought to antagonize dopamine D2 receptors and activate the integrated ...